What we do:
With the aim of discovering molecular probes and drug candidates for allosteric target proteins, Peter Gmeiner’s group (University Erlangen) investigates design, chemical synthesis and pharmacological properties of subtype-selective GPCR ligands, TetR effectors (SFB 473) and bioactive agents for the treatment of prion-related diseases. In this context, radioligand binding studies and functional assays reveal the structural origins of subtype selectivity and intrinsic activity. Within these topics, the Gmeiner laboratory has substantial experience in the design, organic synthesis and biological investigation of bioactive molecules and contributes to highly attractive developments in CNS-active drugs and gene therapy.
